Danish group claims rival used outdated data to support claims that its products were more effective than Wegovy ...
Sana Biotechnology's lead asset still remains to be SC291, repurposed for severe autoimmune disorders instead of blood ...
The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes ...
Carry medicines and other essentials in your hand luggage when travelling by air, says the VDBD. Otherwise, if your checked-in suitcase doesn’t make it to your holiday destination, you’ll be left ...
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers ...
In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers ...
A study at Rutgers University found the medications may be connected to a higher likelihood of ischemic optic neuropathy.
The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes ...
Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and ...
Novo Nordisk sued Eli Lilly, alleging misleading ads unfairly compare doses of Zepbound and Mounjaro with Wegovy and Ozempic.
Finerenone plus empagliflozin combination therapy reduces systolic blood pressure in patients with T2D and chronic kidney disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results